Telehealth Weight Loss/GLP-1 Prescribing: What PMHNPs Can Do in Michigan

The short answer: Yes, psychiatrists can prescribe GLP-1 medications for weight loss — and many are already doing so as part of integrated metabolic-psychiatric care. But like most things in medicine, the reality is more nuanced than a simple yes or no.

If you’re a psychiatrist or PMHNP wondering whether treating obesity falls within your scope, you’re asking the right question at the right time. The explosion of GLP-1s like Wegovy and Ozempic has blurred traditional specialty boundaries, and mental health providers are uniquely positioned to help patients who struggle with both psychiatric conditions and weight management.

Let’s cut through the confusion around scope of practice, state regulations, reimbursement, and whether this makes sense for your practice.

Why Psychiatrists Are Prescribing Weight-Loss Medications

The overlap is bigger than you think. Many of your patients are already dealing with obesity — often because of the medications you prescribed. Atypical antipsychotics, mood stabilizers, and even some antidepressants commonly cause significant weight gain. You’re already monitoring metabolic side effects, checking glucose and lipid panels, and counseling patients about diet and exercise.

So when a patient gains 40 pounds on olanzapine and asks about weight-loss options, is prescribing a GLP-1 ‘outside your scope’? Not if you’ve gained the proper competency.

Dr. Elliott Lewis, a board-certified psychiatrist and obesity medicine specialist, frames it this way: ‘If we truly understand that metabolic and mental health systems are inseparable, then psychiatrists being involved in metabolic treatment makes complete sense.’ He’s not alone — a growing number of psychiatrists are obtaining dual certification in obesity medicine or integrating weight management into their practices.

The psychiatric angle matters. GLP-1 medications aren’t just about weight. Emerging research suggests they may help with:

• Reducing cravings in substance use disorders
• Improving mood and quality of life independent of weight loss
• Decreasing binge-eating behaviors
• Lowering systemic inflammation that affects mental health

And here’s the safety concern everyone asks about: Do GLP-1s increase suicidal ideation? The data says no. A 2025 meta-analysis in JAMA Psychiatry found no increase in depression or suicidality with GLP-1 medications versus placebo. In fact, GLP-1-treated patients showed slightly lower rates of depressive symptoms in clinical trials. The FDA and EMA reviewed safety data and found no causal link to suicidal behavior.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Scope of Practice: The Training Question

The key word here is competency, not specialty title. Your scope of practice isn’t limited to ‘what you did in residency’ — it’s what you’re trained and qualified to do now.

That said, jumping into weight-loss prescribing without additional education would be negligent. If you want to legitimately expand into this area, here’s what psychiatrists are doing:

1. Obesity Medicine Board Certification
The American Board of Obesity Medicine (ABOM) offers certification to physicians of any specialty — yes, including psychiatry. The pathway includes:

• ~60 hours of obesity-specific CME covering metabolic physiology, nutrition science, behavioral interventions, and pharmacotherapy
• Passing a comprehensive board exam
• Demonstrating understanding that obesity isn’t ‘just willpower’ but a complex chronic disease

This certification directly addresses the ‘is this your scope?’ question. You’re no longer a psychiatrist dabbling in weight loss — you’re a physician with formal training in obesity medicine.

2. Targeted CME and Mentorship
Not ready for full certification? Many psychiatrists start by taking CME courses on GLP-1 pharmacology, metabolic monitoring, and obesity treatment protocols. Partnering with an endocrinologist or bariatric specialist for initial consults can help you gain confidence.

3. Staying in Your Lane with Documentation
The safest approach: integrate weight management for patients you’re already treating psychiatrically, especially when weight gain is medication-related. Document clearly that you’re treating the whole patient — obesity management as part of comprehensive psychiatric care, not as a standalone cosmetic service.

Collaborate with the patient’s PCP. Order appropriate labs (TSH, A1C, lipids) to rule out secondary causes of obesity. Refer to cardiology or endocrinology when warranted. This isn’t about becoming a general practitioner — it’s about not ignoring a major health issue in your patient population.

State Regulations: Who Can Prescribe What

Psychiatrists (MD/DO): Full Authority with Caveats

As a licensed physician, you have broad prescriptive authority in all 50 states for FDA-approved weight-loss medications. You can prescribe:

• GLP-1 agonists (semaglutide/Wegovy, liraglutide/Saxenda, tirzepatide)
• Phentermine (Schedule IV controlled substance)
• Other obesity medications (orlistat, naltrexone-bupropion, etc.)

However, state-specific rules still apply:

Florida requires:

• Documented BMI ≥30 (or ≥27 with comorbidities) before prescribing
• A comprehensive physical exam (can be conducted by a delegated APRN/PA)
• Written informed consent
• Follow-up visits at least every 3 months for patients on obesity meds
• Providing the state’s ‘Weight-Loss Consumer Bill of Rights’ brochure

New Jersey mandates:

• Complete history and physical
• Appropriate lab tests
• Assessment and treatment of any underlying psychiatric conditions
• Documented nutritional counseling, exercise plans, and behavior modification — not just pills

Virginia requires:

• Initial physical exam, then follow-up within 30 days of starting medication
• Monthly evaluations for the first few months
• Documented diet and exercise program

These aren’t suggestions — violating these rules can trigger board investigations. Florida especially has a history of disciplining providers for lax weight-loss clinic practices.

PMHNPs: It Depends on Your State

Nurse practitioners face a patchwork of regulations:

Full Practice Authority States (roughly 26 states including Washington, Oregon, New Mexico, Arizona, Colorado, and others): PMHNPs can prescribe weight-loss medications independently after meeting state requirements (typically 2-4 years of supervised practice). However, even in these states, some insurers or pharmacies may require physician sign-off for high-cost GLP-1s — not a legal requirement, but a practical barrier.

Reduced/Restricted Practice States (including Texas, Florida, California, Pennsylvania, Alabama): PMHNPs must have a collaborative agreement or supervising physician to prescribe any medications, including for weight loss.

State-by-State Breakdown:

The collaboration requirement isn’t just paperwork. In Texas, for example, the Prescriptive Authority Agreement must detail:

• Which medications the NP can prescribe (including specific drug classes)
• Communication protocols
• Chart review schedules (typically monthly)
• Quality assurance processes

Violations can result in license discipline for both the NP and supervising physician.

Telehealth Prescribing: Federal Green Light, State Red Lights

Here’s where it gets tricky. The federal government (DEA) extended COVID-era waivers allowing providers to prescribe controlled substances via telehealth through December 31, 2025, with another extension likely through 2026. This means you can prescribe phentermine (Schedule IV) via video visit without an initial in-person exam — at the federal level.

But state law can override federal rules, and several states have stricter requirements:

Florida explicitly prohibits telehealth prescriptions of controlled substances except for:

• Treating psychiatric disorders
• Inpatient/hospice care
• Emergency addiction treatment

Weight loss isn’t on that list. So if you’re prescribing phentermine via telehealth to a Florida patient, you’re violating state law — even though federal DEA rules allow it. (Some providers argue that if the patient has a co-occurring psychiatric diagnosis, it fits the exception, but this is legally uncertain.)

GLP-1 agonists aren’t controlled substances, so they can be prescribed via telehealth in Florida as long as you meet the state’s obesity treatment standards (documented exam, BMI criteria, quarterly follow-ups).

Alabama requires an initial in-person exam for any controlled substance prescription, effectively banning remote phentermine starts.

Mississippi took the unusual step of banning off-label GLP-1 prescribing for weight loss (you must use FDA-approved obesity versions like Wegovy, not diabetes drugs like Ozempic for non-diabetics).

Best Practice for Telehealth:

• Conduct a thorough video evaluation (not just a questionnaire) for initial visits
• Document vital signs (patients can self-report weight, BP; consider requiring recent labs)
• Check your state’s Prescription Drug Monitoring Program (PMP/PDMP) before prescribing controlled substances
• Schedule follow-ups according to state requirements (every 30 days in VA, every 3 months in FL)
• Coordinate with the patient’s PCP when possible
• For controlled substances, verify you’re in compliance with both federal and state telehealth laws

A Mississippi physician lost his license in 2023 for prescribing Ozempic via instant messaging with no audio/video exam. Don’t let convenience override standard of care.

Reimbursement: The Business Case

Insurance coverage for GLP-1 weight-loss medications is expanding rapidly. A few years ago, most insurers excluded obesity drugs. Now, many commercial plans cover GLP-1s like Wegovy, though usually with prior authorization requiring:

• BMI ≥30 (or ≥27 with comorbidities like diabetes, hypertension)
• Documentation of failed lifestyle interventions
• Evidence of a comprehensive weight management plan (diet, exercise, behavioral counseling)

Some plans impose quantity limits — for example, BCBS Texas rolled out a 30-day supply limit for new GLP-1 prescriptions to monitor adherence before approving refills.

The Medicare game-changer: In November 2025, Medicare announced it will begin covering anti-obesity medications including GLP-1s. This is huge. Historically, Medicare Part D explicitly excluded weight-loss drugs. Starting in 2026, millions of Medicare beneficiaries will have access to these medications — meaning psychiatrists serving older populations can now offer this treatment with insurance coverage.

Medicaid coverage varies by state but is expanding. Illinois Medicaid, for example, reimburses APRNs at 100% of physician rates for all services (not the typical 85%), which makes NP-led weight management economically viable.

Billing for visits:

• Use standard E/M codes (99202-99215) based on complexity
• For Medicare patients, obesity counseling codes G0447 (15-minute face-to-face counseling, BMI ≥30) exist but are typically used by PCPs/dietitians
• Psychiatric medication management codes (90833, 90836) can be used if combining therapy
• Telehealth parity laws in California, New York, Illinois, and many other states require insurers to reimburse telehealth visits at the same rate as in-person

Psychiatrists get paid more than NPs — MDs receive 100% of physician fee schedules, while PMHNPs typically receive 85% from Medicare (though some state Medicaid programs and commercial plans pay NPs at parity).

The ROI for providers:

• Initial psychiatric evaluation with med management (CPT 90792): ~$200 Medicare reimbursement
• Follow-up med checks (99213/99214): $75-$150 depending on complexity
• Higher-complexity visits involving metabolic monitoring, lifestyle counseling, and medication adjustment can justify 99215 codes (~$150-$180)

If you’re seeing patients every 4-6 weeks for weight management via telehealth, the economics work — especially when patients are also addressing mental health concerns in the same visits.

Cash-pay is still common for patients whose insurance won’t cover GLP-1s or who want to avoid prior auth hassles. Many telehealth weight-loss services charge monthly memberships ($100-$300/month) that include provider consultations, with medications paid separately. Just be aware: without insurance coverage, branded GLP-1s cost $900-$1,300/month out-of-pocket, limiting your market to affluent patients or those using compounded versions (which come with their own regulatory risks).

The Economics of Patient Acquisition

Let’s talk honestly about how you build a weight-loss practice.

DIY marketing is expensive and uncertain. If you’re thinking about running Google Ads or building SEO to attract weight-loss patients:

• Google Ads for mental health keywords cost $15-40+ per click. Weight-loss keywords are even more competitive. You might pay $20-50 per click, and most clicks won’t convert to booked patients.
• Realistic cost per booked patient through PPC: $200-400+ when you factor in ad spend, optimization, and conversion rates.
• SEO takes 6-12 months of consistent investment (content, technical optimization, backlinks) before generating meaningful organic traffic. Most solo providers don’t have the expertise or budget for this.
• Directory listings (Psychology Today, Zocdoc) charge monthly fees and you compete with hundreds of other providers. Zocdoc charges $35-100+ per booking, plus monthly subscription fees.
• When you account for ALL costs — agency/consultant fees, staff time to handle leads, no-show rates from cold leads, failed campaigns, months of investment before results — true patient acquisition cost through DIY marketing is typically $200-500+ per patient.

This isn’t to say DIY marketing can’t work — if you have the budget ($3,000-5,000/month minimum for serious campaigns), the patience (6-12 months to see ROI), and the expertise (or money to hire it), you can eventually build cost-effective channels. But for most providers, especially those starting out or scaling, it’s a gamble.

Platform-based patient acquisition removes the risk. Services like Klarity Health use a pay-per-appointment model — you only pay when a pre-qualified patient books with you. No upfront marketing spend, no monthly subscription fees, no wasted ad budget on clicks that don’t convert. The key value propositions:

• Pre-qualified patients already matched to your specialty and availability
• No marketing risk — you pay a standard listing fee per appointment, not thousands/month hoping for results
• Built-in telehealth infrastructure (no separate platform costs, EHR integration, billing support)
• Both insurance and cash-pay patient flow depending on your preference
• You control your schedule — only accept appointments when you want them

Instead of spending $3,000-5,000/month on marketing with uncertain results, you pay only when you actually see patients. That’s guaranteed ROI vs. gambling on marketing channels that take months to prove out.

Think of it this way: if you acquire 10 new patients per month through a platform at a per-appointment fee, you know exactly what you’re paying and you’re earning revenue immediately. If you spend $4,000/month on Google Ads, you might get 10 patients — or you might get 2, and you won’t know for months whether the campaign is working.

For weight-loss services especially, where patient acquisition is competitive and expensive, a platform that handles the marketing removes a massive headache and financial risk.

Practical Considerations

Is this worth it for your practice?

Consider these questions:

1. Do you have patients who would benefit?
If you’re treating patients on antipsychotics, mood stabilizers, or anyone struggling with medication-induced weight gain, you already have a population that needs this.

2. Are you willing to invest in training?
At minimum, you should complete CME on GLP-1 pharmacology, contraindications (pregnancy, pancreatitis history, thyroid cancer risk), and side effect management. Ideally, pursue ABOM certification to solidify your expertise.

3. Can you handle the administrative load?
Weight-loss prescribing involves:

• Prior authorizations (if billing insurance)
• PDMP checks (for controlled substances)
• Quarterly follow-ups (at minimum)
• Coordinating labs
• Counseling on diet/exercise (or partnering with nutritionists)

If you’re already stretched thin, adding this service without support staff or a platform to streamline workflows could burn you out.

4. Does your state allow it?
If you’re a PMHNP in Texas or Florida, you’ll need a collaborating physician. If you’re in a state that prohibits telehealth controlled substance prescribing, phentermine is off the table (but GLP-1s aren’t controlled, so still an option).

5. What’s your liability comfort level?
Weight-loss medications have side effects — GI issues, gallbladder problems, rare cases of pancreatitis. You’ll need to screen appropriately, monitor, and document thoroughly. If you’re not comfortable managing metabolic issues or you can’t easily refer to specialists when needed, this may not be your lane.

The Bottom Line

Yes, psychiatrists can prescribe GLP-1s and other weight-loss medications — and with proper training and compliance, there’s a strong case for integrating this into psychiatric practice. The overlap between mental health and metabolic health is undeniable, and patients benefit from providers who address both.

But this isn’t about slapping ‘weight loss’ on your website and churning out Ozempic prescriptions. It’s about:

• Gaining real competency through education and certification
• Following state-specific rules (BMI documentation, informed consent, follow-up schedules)
• Using telehealth appropriately (knowing when your state allows remote controlled substance prescribing)
• Integrating treatment thoughtfully into your existing patient care, not running a separate cosmetic clinic
• Choosing sustainable patient acquisition — whether that’s DIY marketing (if you have the budget and patience) or a platform that delivers pre-qualified patients without the financial risk

If you’re a psychiatrist or PMHNP looking to expand your scope responsibly, weight management can be a valuable addition to your practice. It’s clinically meaningful (you’re already dealing with the consequences of psych med weight gain), increasingly reimbursable (with Medicare coverage coming online), and in high demand.

Just make sure you’re doing it the right way — with training, compliance, and a clear strategy for reaching patients who need this care.

Ready to explore how Klarity Health can connect you with patients seeking integrated psychiatric and metabolic care? Our platform handles patient acquisition, telehealth infrastructure, and credentialing — so you can focus on providing great care without gambling thousands on marketing that may or may not work. Learn more about joining Klarity’s provider network.

FAQ

Can psychiatrists legally prescribe Wegovy or Ozempic for weight loss?
Yes. Psychiatrists (MD/DO) have full prescriptive authority for FDA-approved medications in all states. Wegovy is FDA-approved for obesity; Ozempic is approved for diabetes but often prescribed off-label for weight loss (though Mississippi and a few states have restricted this). As long as you meet state clinical standards (documented BMI criteria, informed consent, monitoring), it’s legal.

Do I need special certification to prescribe GLP-1s?
No special license is required beyond your medical degree and DEA registration. However, obtaining training or certification in obesity medicine (like ABOM) demonstrates competency and reduces scope-of-practice concerns. Many psychiatrists pursue this to legitimize their expanded scope.

Can PMHNPs prescribe weight-loss medications independently?
It depends on your state. In full-practice-authority states (like Washington, Arizona, New Mexico, Colorado), yes — after meeting experience requirements. In restricted states (Texas, Florida, Pennsylvania, Alabama), you must have a collaborative agreement with a physician. Even in FPA states, some insurers may require physician involvement for GLP-1 prior authorizations.

Is prescribing phentermine via telehealth legal?
Federally, yes (through at least 2025-2026 under DEA waivers). But state law can prohibit it. Florida bans telehealth controlled substance prescribing except for psychiatric treatment (and it’s unclear if weight loss qualifies). Alabama requires in-person exams for controlled substances. Check your state’s telehealth laws before prescribing phentermine remotely.

Will insurance cover GLP-1 medications I prescribe?
Increasingly, yes — but with prior authorization. Commercial plans often cover Wegovy/Saxenda if patients meet BMI criteria (≥30 or ≥27 with comorbidities) and you document lifestyle interventions. Medicare will begin covering anti-obesity medications in 2026. Medicaid coverage varies by state. Expect to complete prior auth forms justifying medical necessity.

What are the most common state-specific rules I need to know?

• Florida: BMI documentation, written consent, 3-month follow-up intervals, mandatory patient brochure
• New Jersey: Comprehensive psych assessment, nutrition/exercise counseling documented
• Virginia: 30-day initial follow-up, monthly visits for first few months
• Texas: Physician collaboration required for NPs, PDMP checks for controlled substances
• Always check your state medical board website for obesity treatment guidelines.

How much can I earn from weight-loss medication management?
It varies. If billing insurance, follow-up visits typically reimburse $75-$150 (99213-99215 E/M codes). Initial evaluations can be $150-$200+. If you see 4 weight-loss patients per week for 15-20 minute med checks at $100/visit average, that’s $1,600/month gross revenue — before factoring in time for prior auths and follow-up coordination. Cash-pay models charge $100-$300/month for consultations (plus medication costs).

Do I need to partner with a primary care doctor or endocrinologist?
Not legally required (if you’re an MD), but it’s smart practice. Coordinating with the patient’s PCP ensures you’re not missing underlying medical issues and that metabolic monitoring (labs, etc.) is being handled appropriately. If complications arise (severe pancreatitis, gallbladder issues), having a referral relationship with GI or surgery is important.

What’s the liability risk of prescribing weight-loss medications?
Similar to prescribing any medication — you need to screen for contraindications (pregnancy, personal/family history of thyroid cancer for GLP-1s, uncontrolled hypertension for phentermine), monitor for side effects, and document appropriately. GLP-1s have generally good safety profiles but can cause GI issues, gallbladder disease, and rarely pancreatitis. Ensure patients understand risks through informed consent. Malpractice risk is manageable if you practice within accepted guidelines.

Can I prescribe weight-loss medications to patients I’m not treating psychiatrically?
Technically yes (if you’re an MD with obesity medicine training), but it raises scope questions. Safest approach: integrate weight management for patients already under your psychiatric care, especially when weight gain is medication-related. Running a standalone weight-loss clinic as a psychiatrist without obesity medicine certification could draw scrutiny. Document that you’re treating the whole patient, not just offering cosmetic prescriptions.

References

1. MedicalDirector Co. (2025). ‘How Much Does a Collaborative Physician Cost for Weight Loss, Telehealth, and Medspas? 2025 Definitive Guide.’ Retrieved from https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/

2. MedicalDirector Co. (2025). ‘Florida Weight Loss Clinic and Telehealth Compliance Guide (2025).’ Retrieved from https://www.medicaldirectorco.com/florida-weight-loss-clinic-and-telehealth-compliance-guide-2025/

3. MedicalDirector Co. (2025). ‘Texas Weight Loss Clinic & Telehealth Compliance Guide (2025).’ Retrieved from https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/

4. Florida Administrative Code Rule 64B15-14.004 (Effective Aug 8, 2022). ‘Standards for Prescription of Obesity Drugs.’ Retrieved from https://www.law.cornell.edu/regulations/florida/Fla-Admin-Code-Ann-R-64B15-14-004

5. Foley & Lardner LLP (July 24, 2023). ‘A Changing Regulatory and Reimbursement Landscape for Weight-Loss Drugs.’ Mondaq. Retrieved from https://www.mondaq.com/unitedstates/healthcare/1447512/a-changing-regulatory-and-reimbursement-landscape-for-weight-loss-drugs

6. RxAgent.co (Dec 16, 2025). ‘Federal Permission, State Prohibition: The 2026 Telehealth Compliance Trap.’ Retrieved from https://rxagent.co/blog/telehealth-compliance-trap

7. Phillips, S.J. (Jan 2024). ’36th Annual APRN Legislative Update: Improving Access Through Removing Barriers to Practice.’ The Nurse Practitioner, 49(1). Retrieved from https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx

8. Lewis, E., MD (Jan 4, 2026). ‘Should Psychiatrists Prescribe GLP-1s? An Evidence-Based Perspective.’ DrLewis.com. Retrieved from https://drlewis.com/glp-1-medications-psychiatry/

9. Lewis, E., MD (Nov 26, 2025). ‘GLP-1 Medications & Mental Health: Facts vs Myths.’ DrLewis.com. Retrieved from https://drlewis.com/glp-1-mental-health/

10. Axios (Nov 18, 2024). ‘COVID-era telehealth prescribing extended again.’ Retrieved from https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall

11. Axios (Nov 6, 2025). ‘Trump announces Medicare coverage of weight-loss drugs.’ Retrieved from https://www.axios.com/2025/11/06/medicare-coverage-weight-loss-glp1-ozempic-trump

12. Associated Press (Nov 26, 2024). ‘Biden proposes Medicare and Medicaid cover costly weight-loss drugs.’ AP News. Retrieved from https://apnews.com/article/caaa2f888435af1d32bedb83e9ddbc0a

13. TheraThink (2026). ‘Insurance Reimbursement Rates for Psychiatrists [2026].’ Retrieved from https://therathink.com/insurance-reimbursement-rates-for-psychiatrists/

14. Blue Cross Blue Shield of Texas (Oct 4, 2024). ‘Pharmacy Supply Limit for GLP-1 Receptor Agonists Used for Obesity.’ Provider Notice. Retrieved from https://www.bcbstx.com/provider/education/education/news/2024/10-04-24-pharmacy-supply-limit-glp1-obesity

Source:

• https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/#:~:text=The%20answer%20is%20almost%20always,yes
• https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/#:~:text=Nurse%20Practitioners%20
• https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx#:~:text=The%20Pennsylvania%20BON%20grants%20CRNPs%2C,more%20physicians%20to%20deliver%20healthcare
• https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx#:~:text=The%20Illinois%20Department%20of%20Financial,collaborative%20agreement%20following%20a%20TTP
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20DEA%20gave%20us%20the,evaluation%20at%20the%20federal%20level
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=Despite%20federal%20DEA%20waivers%20extending,traps%20for%20digital%20health%20providers
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=1.%20Florida%3A%20The%20%22No,for%20Stimulants
• https://www.mondaq.com/unitedstates/healthcare/1447512/a-changing-regulatory-and-reimbursement-landscape-for-weight-loss-drugs#:~:text=New%20Jersey%20law%20requires%20that,and%20identify%20the%20risks%20associated
• https://drlewis.com/glp-1-medications-psychiatry/#:~:text=You%20know%20these%20drugs,disorders%2C%20and%20possibly%20depression%20itself
• https://drlewis.com/glp-1-mental-health/#:~:text=Now%20let%E2%80%99s%20talk%20about%20potential,where%20things%20get%20really%20interesting